Insmed (NASDAQ:INSM) Given New $112.00 Price Target at The Goldman Sachs Group

Insmed (NASDAQ:INSM - Free Report) had its price objective boosted by The Goldman Sachs Group from $100.00 to $112.00 in a report released on Wednesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company's stock.

Other equities analysts have also recently issued research reports about the company. Bank of America raised their price objective on Insmed from $94.00 to $109.00 and gave the company a "buy" rating in a report on Wednesday. UBS Group reduced their price objective on Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a report on Friday, May 9th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Insmed in a research note on Wednesday, February 19th. Truist Financial upped their target price on Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Finally, Morgan Stanley upped their price target on shares of Insmed from $90.00 to $102.00 and gave the stock an "overweight" rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, Insmed presently has an average rating of "Moderate Buy" and an average price target of $104.81.

Insmed Price Performance

Shares of INSM stock traded up $1.85 during trading hours on Wednesday, hitting $98.73. The company had a trading volume of 5,318,455 shares, compared to its average volume of 2,164,284. The firm has a market capitalization of $17.98 billion, a price-to-earnings ratio of -17.66 and a beta of 0.80. Insmed has a 12 month low of $60.40 and a 12 month high of $100.00. The firm's fifty day moving average is $71.41 and its 200 day moving average is $73.61. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The firm had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm's quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.06) earnings per share. On average, sell-side analysts predict that Insmed will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 18,750 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $77.03, for a total transaction of $1,444,312.50. Following the transaction, the chief executive officer now directly owns 334,186 shares in the company, valued at approximately $25,742,347.58. The trade was a 5.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Sara Bonstein sold 8,870 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $67.81, for a total transaction of $601,474.70. Following the completion of the sale, the chief financial officer now directly owns 109,993 shares in the company, valued at $7,458,625.33. This trade represents a 7.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 319,932 shares of company stock worth $25,733,693 over the last three months. Corporate insiders own 3.00% of the company's stock.

Hedge Funds Weigh In On Insmed

A number of large investors have recently made changes to their positions in INSM. Cullen Frost Bankers Inc. boosted its position in shares of Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 221 shares during the last quarter. Elequin Capital LP bought a new stake in shares of Insmed in the fourth quarter worth $28,000. Steward Partners Investment Advisory LLC increased its stake in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 163 shares during the last quarter. V Square Quantitative Management LLC increased its stake in Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 248 shares during the last quarter. Finally, NBC Securities Inc. bought a new stake in Insmed during the first quarter valued at $49,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.